

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM319499

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Ampio Pharmaceuticals, Inc.		10/03/2014	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Vyrix Pharmaceuticals, Inc.		
Street Address:	5445 DTC Parkway, Suite 925		
City:	Greenwood Village		
State/Country:	COLORADO		
Postal Code:	80111		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	85874868	POPE	
CORRESPONDENCE DATA			
Fax Number:	3038630223		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3038639700		
Email:	mtrudell@sheridanross.com		
Correspondent Name:	Miriam D. Trudell, Sheridan Ross P.C.		
Address Line 1:	1560 Broadway, Suite 1200		
Address Line 4:	Denver, COLORADO 80211		
ATTORNEY DOCKET NUMBER:	4172-110		
NAME OF SUBMITTER:	Miriam D. Trudell		
SIGNATURE:	/Miriam D. Trudell/		
DATE SIGNED:	10/08/2014		
Total Attachments: 2			
source=2014.10.03 - Trademark Assignment (Executed)#page1.tif			
source=2014.10.03 - Trademark Assignment (Executed)#page2.tif			

CH \$40.00 85874868

TRADEMARK ASSIGNMENT

This is an Assignment by Ampio Pharmaceuticals, Inc., ("Ampio") a Delaware corporation, having an address of 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111, to Vyrrix Pharmaceuticals, Inc., ("Vyrrix") a Delaware corporation, having an address of 5445 DTC Parkway, Suite 925, Greenwood Village, CO 80111 USA.

WHEREAS, Ampio is the owner of the trademark, and U.S. application therefor, listed in Appendix A ("MARK") and is desirous of assigning the MARK to Vyrrix;

WHEREAS, Vyrrix is desirous of acquiring all right, title and interest in the MARK and the U.S. application therefor listed in Appendix A; and


WHEREAS Vyrrix is the successor to the portion of the ongoing and existing business of Ampio to which the MARK, and the U.S. application therefor listed in Appendix A, pertain.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Ampio does hereby assign to Vyrrix all right, title and interest in and to the MARK together with any and all goodwill of the business symbolized by the MARK and the U.S. application therefor.

AMPIO PHARMACEUTICALS, INC.

Date: 10/3/14

By: _____


Josh Disbrow
Chief Operating Officer

APPENDIX A

U.S. Trademark Application Serial No. 85/874,868 for “POPE” in:

- Class 16 for “Printed matter, namely, reports, guidelines, manuals, brochures, booklets, pamphlets and protocols in the fields of medical research, clinical trials, medical conditions, pharmaceutical evaluation and pharmaceutical efficacy; printed medical questionnaires on medical history assessment, medical trial results, pharmaceutical evaluation and pharmaceutical efficacy; printed surveys and protocols used for collection of medical data and medical history; printed medical records; publications, namely, printed forms in the fields of medical assessment; printed matter, namely, reports, guidelines, manuals, brochures, booklets, pamphlets, questionnaires and protocols in the field of premature ejaculation; questionnaires for medical research and pharmaceutical efficacy purposes”;
- Class 41 for “Online publications, namely, reports, guidelines and protocols in the fields of medical research, clinical trials, medical conditions, pharmaceutical evaluation and pharmaceutical efficacy; online medical questionnaires on medical history assessment, medical trial results, pharmaceutical evaluation and pharmaceutical efficacy; online publications, namely, electronic forms in the fields of medical assessment; providing online publications, namely, questionnaires for evaluating the efficacy of a therapeutic treatment and questionnaires for evaluating the efficacy of pharmaceuticals; publication of printed matter, namely, reports, journals, protocols and questionnaires with the results of clinical studies involving pharmaceutical preparations; publication of electronic matter, namely, electronic magazines, electronic journals, electronic protocols and electronic questionnaires with the results of clinical studies involving pharmaceutical preparations; educational services, namely, providing classes, training and lectures in the field of clinical research; providing online publications, namely, questionnaires in the field of premature ejaculation for assessing symptoms for medical research purposes; providing online publications, namely, questionnaires in the premature ejaculation for assessing symptoms for monitoring patients' response to treatment; online publications, namely, questionnaires for medical research and pharmaceutical efficacy purposes”;
- Class 42 for “Scientific research, namely, arranging a protocol of clinical development and experimentation relating to pharmaceutical products and their efficacy; scientific research, namely, arranging a protocol of study relating to pharmaceutical products and their efficacy; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing medical and scientific research information in the field of clinical trials; medical research; pharmaceutical research services”;
- Class 44 for “Consulting services in the field of health care; medical consulting services in the field of clinical trials”; and
- Class 45 for “Licensing of intellectual property.”